Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 4 results out of 4

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

Denifanstat by Sagimet Biosciences for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Denifanstat in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Denifanstat by Sagimet Biosciences for Liver Cirrhosis: Likelihood of Approval

Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase I for Liver Cirrhosis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Denifanstat in Liver Cirrhosis

Data Insights

Denifanstat by Sagimet Biosciences for Glioblastoma Multiforme (GBM): Likelihood of Approval

Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Denifanstat in Glioblastoma Multiforme (GBM)

Data Insights

Denifanstat by Sagimet Biosciences for Glioblastoma Multiforme (GBM): Likelihood of Approval

Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...

Sections

Sections

Sections

Sections

Sections

Company Profiles

Denifanstat by Sagimet Biosciences for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Denifanstat by Sagimet Biosciences for Liver Cirrhosis: Likelihood of Approval

Denifanstat by Sagimet Biosciences for Glioblastoma Multiforme (GBM): Likelihood of Approval

Denifanstat by Sagimet Biosciences for Glioblastoma Multiforme (GBM): Likelihood of Approval